Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AGRONOMICS LIMITED Net Asset Value 2023

Aug 2, 2023

7474_nav_2023-08-02_db4e4bce-e814-4904-ab82-f71df726c17a.html

Net Asset Value

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 9709H

Agronomics Limited

02 August 2023

2 August 2023

Agronomics Limited

("Agronomics" or the "Company")

Net Asset Value calculation at 30 June 2023

Agronomics Limited (AIM:ANIC), the leading listed company focused on the field of cellular agriculture, announces that its unaudited Net Asset Valuation ("NAV") calculation as at closing on 30 June 2023 was 15.80 pence per share, a 2% decrease from 16.14 pence per share at 31 March 2023. Net Assets stand at £157 million, including investments of £129 million and uninvested cash of £28 million.

The share price of 10.40 pence at the 30 June 2023 close represents a discount of 34% to the NAV per share. The average discount to NAV per share over the last 12-month period was 20%. Under IFRS, the Company's unquoted investments are generally carried at cost or the most recent priced funding round.

Richard Reed, Chairman of Agronomics, commented: -

"We are pleased to report that the Net Asset Value of our portfolio has remained relatively stable in the past three months, given the macro-economic backdrop. This reflects the quality of our portfolio companies, as well as increasing global investment into the cellular agriculture sector led by major food companies seeking reduced price volatility and nation states seeking food security. This is a trend we expect to continue, further boosted by regulatory developments, such as the recent approval of cultivated chicken for sale in the US."

Financing

During the quarter ended 30 June 2023, the Company received notification of warrants being exercised. A total of 905,184 new ordinary shares were issued following the warrant exercise, for proceeds of £272,177.07. These funds, together with existing cash resources, will be utilised to provide finance for opportunities within the field of cellular agriculture, both by supporting existing companies, as well as identifying new opportunities in which to invest.

On 1 June 2023, the Company announced a 12-month extension for the final exercise date of those unexercised warrants granted on 1 June 2021 and 8 December 2021. These warrants will now expire on 1 June 2024 and 8 December 2024, respectively.

Investment review

On 12 April 2023, the Company announced that Liberation Labs Holdings Inc ("Liberation Labs"), the large-scale precision fermentation contract manufacturer, secured $30 million in equipment funding for the first dedicated, purpose-built, commercial precision fermentation plant globally for food production.

On 4 May 2023, the Company completed a £1 million investment in Good Dog Food Limited ("GDF") as part of its £3.6 million Seed financing round. Agronomics acquired 8,768 shares in GDF representing 42.4% of the company. Investors that participated in this latest round of financing include Siddhi Capital, a prominent and highly respected investor in innovative food products and technologies, and Pets at Home, UK's leading pet retailer. Jim Mellon, an Executive Director of Agronomics and a 2.99% shareholder in GDF, also participated in the fundraise, with a £300,000 investment.

On 15 June 2023, the Company invested AUD 2.5 million in HydGene Renewables Pty Ltd ("HydGene"), a developer of synthetic biology to engineer microorganisms for use in hydrogen production. The investment is part of HydGene's AUD 6 million Seed financing round. The investment is in line with Agronomics' wider focus on investing in opportunities seeking to minimise the irreversible damage to the natural environment and will result in Agronomics holding 188,239 Series Seed Preferred Shares and owning, on a fully diluted basis, 12.50% of HydGene.

On 22 June 2023, the Company announced that CellX Limited ("CellX") raised US$ 6.5 million in new funding from third parties to accelerate the development of its cultivated meat products as they near commercialisation. Agronomics has an equity ownership of 4.98% on a fully diluted basis in CellX.

Unaudited to

30 June 2023

£
Current Assets
Investments 128,758,644
Uninvested cash and deposits 28,280,418
Trade and other receivables 57,146
Current Liabilities
Trade and other creditors (224,718)
Net Assets 156,871,491
Capital and Reserves
Share capital 993
Share premium 134,481,365
Retained earnings 22,389,133
Net assets 156,871,491
Shares in Issue 993,152,034
Net Asset Value per share 15.80 pence

The quoted investments within the portfolio are valued under IFRS at bid price.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014, as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

For further information please contact:

Agronomics

Limited
Beaumont

Cornish Limited
Canaccord Genuity Limited Cenkos

Securities Plc
Peterhouse Capital

Limited
SEC Newgate
The Company Nomad Joint Broker Joint Broker Joint Broker Public Relations
Richard Reed

Denham Eke
Roland Cornish

James Biddle
Andrew Potts

Harry Rees

Alex Aylen (Head of Equities)
Giles Balleny

Michael Johnson
Lucy Williams

Charles Goodfellow
Bob Huxford

George Esmond

Anthony Hughes

Alice Cho
+44 (0) 1624 639396

[email protected]
+44 (0) 207 628 3396 +44 (0) 207 523 8000 +44 (0) 207 397 8900 +44 (0) 207 469 0936 [email protected]

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NAVUAANROOUWRAR